Immune-Onc Therapeutics Overview

  • Founded

  • 2016

Founded
  • Status

  • Private

  • Employees

  • 39

Employees
  • Latest Deal Type

  • Series B3

  • Latest Deal Amount

  • $25M

  • Investors

  • 21

Immune-Onc Therapeutics General Information

Description

Operator of a clinical-stage cancer immunotherapy company intended to translate unique scientific insights into myeloid cell biology and immune inhibitory receptors. The company has a focused platform approach and differentiated pipeline and has developed first-in-class biotherapeutics that disarm immune suppression in the tumor microenvironment, enabling patients to have access to new immunomodulatory.

Contact Information

Website
www.immune-onc.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
  • 795 San Antonio Road
  • Palo Alto, CA 94303
  • United States
+1 (650) 000-0000

Immune-Onc Therapeutics Timeline

2020202120222023
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Immune-Onc Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
9. Later Stage VC (Series B3) 05-Jan-2023 $25M 00000 00000 Completed Clinical Trials - Phase 1
8. Grant 20-Apr-2021 000 00000 Completed Clinical Trials - Phase 1
7. Later Stage VC (Series B1) 30-Mar-2021 000.00 00000 00000 Completed Clinical Trials - General
6. Grant 04-Aug-2020 00.000 000.00 Completed Pre-Clinical Trials
5. Grant 01-Aug-2020 00.000 000.00 Completed Pre-Clinical Trials
4. Debt - PPP 13-Apr-2020 000.00 Completed Pre-Clinical Trials
3. Early Stage VC (Series B) 18-Sep-2018 0000 000.00 000.00 Completed Pre-Clinical Trials
2. Accelerator/Incubator 28-Jun-2017 $500K $7.5M Completed Product Development
1. Early Stage VC (Series A) 01-Sep-2016 $7M $7M 0000 Completed Product Development
To view Immune-Onc Therapeutics’s complete valuation and funding history, request access »

Immune-Onc Therapeutics Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series B3 00,000,000 00.000000 00 00.00 00.00 00 00.00 0.00
Series B2 0,000,000 00.000000 00 00.00 00.00 00 00.00 0.000
Series B1 00,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
Series B 20,988,105 $0.000100 6% $1.58 $1.58 1x $1.58 17.37%
Series A 8,634,934 $0.000100 6% $0.81 $0.81 1x $0.81 7.15%
To view Immune-Onc Therapeutics’s complete cap table history, request access »

Immune-Onc Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operator of a clinical-stage cancer immunotherapy company intended to translate unique scientific insights into myeloid
Drug Discovery
Palo Alto, CA
39 As of 2023
00000
0000 0000-00-00
00000000000 00000

000000

n reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.
0000 000000000
South San Francisco, CA
00 As of 0000
00000
000000 - 000 00000

000000

met, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et
0000 000000000
South San Francisco, CA
00 As of 0000
00000
0000 0000-00-00
0000000000 0 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Immune-Onc Therapeutics Competitors (36)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Pionyr Immunotherapeutics Venture Capital-Backed South San Francisco, CA 00 00000 000000 - 000 00000
000000 00000000000 Venture Capital-Backed South San Francisco, CA 00 00000 0000000000 0 00000
00000 000000000 Venture Capital-Backed Nahariya, Israel 00 000.00 00000000000 000.00
000000000000 Venture Capital-Backed Seattle, WA 00 00000 000000000 00000
000 00000000000000 Formerly VC-backed South San Francisco, CA 000 00000 000000000 00000
You’re viewing 5 of 36 competitors. Get the full list »

Immune-Onc Therapeutics Patents

  • 3

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 000

    Granted

  • 1

    Pending

  • 000

    Expiring in next 12 mo

Immune-Onc Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2021236302-A1 Novel anti-lilrb4 antibodies and derivative products Pending 12-Mar-2020 00000000000
CA-3175140-A1 Novel anti-lilrb4 antibodies and derivative products Pending 12-Mar-2020 00000000000
EP-4118120-A2 Novel anti-lilrb4 antibodies and derivative products Pending 12-Mar-2020 C07K16/2803

Immune-Onc Therapeutics Executive Team (8)

Name Title Board Seat Contact Info
Charlene Liao Ph.D Co-Founder, Chief Executive Officer, President & Chairman
Christopher Whitmore Chief Financial Officer
Guoliang Yu Ph.D Co-Founder & Board Member
Chengcheng Zhang Ph.D Scientific Founder
Paul Woodard MD Chief Medical Officer
You’re viewing 5 of 8 executive team members. Get the full list »

Immune-Onc Therapeutics Board Members (10)

Name Representing Role Since
Austin Gurney Ph.D Immune-Onc Therapeutics Board Member 000 0000
Barbara Klencke MD Self Board Member 000 0000
Bing Yao Immune-Onc Therapeutics Board Member 000 0000
Charlene Liao Ph.D Immune-Onc Therapeutics Co-Founder, Chief Executive Officer, President & Chairman 000 0000
Dave Chenn Oceanpine Capital Board Member 000 0000
You’re viewing 5 of 10 board members. Get the full list »

Immune-Onc Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Immune-Onc Therapeutics Investors (21)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Proxima Ventures (China) Venture Capital Minority 000 0000 000000 0
Triwise Capital Venture Capital Minority 000 0000 000000 0
Wuxi Biologics Corporation Minority 000 0000 000000 0
Leukemia & Lymphoma Society Not-For-Profit Venture Capital Minority 000 0000 000000 0
Oceanpine Capital Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 21 investors. Get the full list »

Ready to get started?

Request a free trial